Synthesis of Novel 2-(Isopropylamino)thiazol-4(5H)-one Derivatives and Their Inhibitory Activity of 11β-HSD1 and 11β-HSD2 in Aspect of Carcinogenesis Prevention
Related Experiment Video
Updated: Dec 8, 2025

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
Daria Kupczyk1, Renata Studzińska2, Rafał Bilski1
1Department of Medical Biology and Biochemistry, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-092 Bydgoszcz, Poland.
Abstract:
Glucocorticoid metabolism at the tissue level is regulated by two isoenzymes 11β-hydroxysteroid dehydrogenase (11β-HSD), which mutually convert biologically active cortisol and inactive cortisone. Recent research is focused on the role of 11β-HSD1 and 11β-HSD2 as autocrine factors of tumor cell proliferation and differentiation. Herein, we report the synthesis of novel 2-(isopropylamino)thiazol-4(5H)-one derivatives and their inhibitory activity for 11β-HSD1 and 11β-HSD2. The derivative containing the spiro system of thiazole and cyclohexane rings shows the highest degree of 11β-HSD1 inhibition (54.53% at 10 µM) and is the most selective inhibitor of this enzyme among the tested compounds. In turn, derivatives containing ethyl and n-propyl group at C-5 of thiazole ring inhibit the activity of 11β-HSD2 to a high degree (47.08 and 54.59% at 10 µM respectively) and are completely selective. Inhibition of the activity of these enzymes may have a significant impact on the process of formation and course of tumors. Therefore, these compounds can be considered as potential pharmaceuticals supporting anti-cancer therapy.
Insights
Novel thiazolone derivatives show promise as cancer therapeutics by inhibiting 11β-hydroxysteroid dehydrogenase (11β-HSD) enzymes involved in glucocorticoid metabolism and tumor growth.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Oncology
Background:
- Tissue-level glucocorticoid metabolism is controlled by 11β-hydroxysteroid dehydrogenase (11β-HSD) isoenzymes, interconverting cortisol and cortisone.
- 11β-HSD1 and 11β-HSD2 are implicated as autocrine factors in tumor cell proliferation and differentiation.
- Targeting these enzymes presents a potential strategy for anti-cancer therapy.
Purpose of the Study:
- To synthesize novel 2-(isopropylamino)thiazol-4(5H)-one derivatives.
- To evaluate the inhibitory activity and selectivity of these derivatives against 11β-HSD1 and 11β-HSD2.
Main Methods:
- Synthesis of novel 2-(isopropylamino)thiazol-4(5H)-one derivatives.
- In vitro assessment of enzyme inhibition for 11β-HSD1 and 11β-HSD2.
- Determination of compound selectivity for each isoenzyme.
Main Results:
- A spirocyclic thiazole-cyclohexane derivative exhibited the highest 11β-HSD1 inhibition (54.53% at 10 µM) and selectivity.
- Derivatives with ethyl and n-propyl groups at C-5 of the thiazole ring showed significant 11β-HSD2 inhibition (47.08% and 54.59% at 10 µM, respectively) with complete selectivity.
- These findings highlight specific structure-activity relationships for 11β-HSD inhibition.
Conclusions:
- The synthesized thiazolone derivatives demonstrate potent and selective inhibition of 11β-HSD1 and 11β-HSD2.
- Modulating 11β-HSD activity through these compounds may impact tumor formation and progression.
- These novel derivatives hold potential as adjunctive pharmaceuticals in anti-cancer therapy.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Thiazide-Class Diuretics
Mutagenicity and Carcinogenicity

